Pfizer Inc.
AQUEOUS ANTI-PD-L1 ANTIBODY FORMULATION
Last updated:
Abstract:
The present invention relates to a novel anti-PD-L1 antibody formulation. In particular, the invention relates to an aqueous pharmaceutical formulation of the anti-PD-L antibody Avelumab.
Status:
Application
Type:
Utility
Filling date:
6 Mar 2018
Issue date:
16 Jan 2020